About SMT
SMT is a company based in Surat (India) founded in 1998. It operates as a Direct-to-Consumer (D2C) and Professional Services. SMT has raised $57.22 million across 4 funding rounds from investors including SBI Mutual Fund, Kotak Mahindra Bank and Plutus. The company has 1,090 employees as of February 08, 2025. SMT has completed 2 acquisitions, including Vascular Concepts and Zarek. SMT offers products and services including Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit. SMT operates in a competitive market with competitors including InspireMD, Vesper Medical, Endospan, Biosensors International and Veryan Medical, among others.
- Headquarter Surat, India
- Employees 1090 as on 08 Feb, 2025
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sahajanand Medical Technologies Ltd.
- Date of Incorporation 18 Oct, 2001
- Jurisdiction Surat, Gujarat, India
-
Annual Revenue
$106.25 M (USD)13.55as on Mar 31, 2024
-
Net Profit
-$859.11 K (USD)-161.62as on Mar 31, 2024
-
EBITDA
$12.88 M (USD)-3.01as on Mar 31, 2024
-
Total Equity Funding
$57.22 M (USD)
in 4 rounds
-
Latest Funding Round
$20.87 M (USD), Unspecified
Jan 19, 2023
-
Investors
SBI Mutual Fund
& 78 more
-
Employee Count
1090
as on Feb 08, 2025
-
Investments & Acquisitions
Vascular Concepts
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SMT
SMT offers a comprehensive portfolio of products and services, including Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit.
Advanced coronary stent used for arterial blockages treatment.
Valve designed for treating severe aortic stenosis conditions.
Device used to close atrial septal heart defects.
Balloon expandable stent for renal and biliary issues.
Funding Insights of SMT
SMT has successfully raised a total of $57.22M across 4 strategic funding rounds. The most recent funding activity was a Unspecified round of $20.87 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SMT
SMT has secured backing from 79 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include SBI Mutual Fund, Kotak Mahindra Bank and Plutus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
Commercial banking services are offered to corporate and retail customers.
|
Locked | Locked | Locked | |
|
Provides mutual funds management and financial advisory services.
|
Locked | Locked | Locked |
Investor details for SMT
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SMT
SMT has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Vascular Concepts and Zarek.
Investment portfolio details for SMT
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Coronary and peripheral stents are manufactured for arterial disease treatments.
|
Locked | Locked | 1992 | Locked | |
|
-
|
Locked | Locked | 0 | Locked |
Complete acquisition details for SMT
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SMT
Detailed financials for SMT
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Smt Comparisons
Peer comparison for SMT
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SMT
SMT operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as InspireMD, Vesper Medical, Endospan, Biosensors International and Veryan Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Proprietary stent systems with bio-stable mesh are developed and commercialized.
|
|
| Locked | Locked | Locked |
Venous stent system is developed for deep vein disease treatment.
|
|
| Locked | Locked | Locked |
Endovascular stent graft systems for aortic aneurysm repair are developed.
|
|
| Locked | Locked | Locked |
Products for interventional cardiology and critical care procedures
|
|
| Locked | Locked | Locked |
Three-dimensional vascular stents for peripheral vascular disease are developed.
|
Detailed competitors of SMT
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Smt
Complete news archive for SMT
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SMT
SMT was founded in 1998 and raised its 1st funding round 11 years after it was founded.
SMT is headquartered in Surat, India. It is registered at Surat, Gujarat, India.
Bhargav Kotadia is the current CEO of SMT.
SMT is a funded company, having raised a total of $57.22M across 4 funding rounds to date.
As of Feb 08, 2025, the latest employee count at SMT is 1,090.
Annual revenue of SMT is $106.25M as on Mar 31, 2024.
SMT, officially known as Sahajanand Medical Technologies Ltd., is engaged in the development and manufacturing of minimally invasive cardiovascular devices. The company operates within the healthcare sector, focusing on coronary stents, structural heart devices, and peripheral intervention solutions. Products such as Supraflex Cruz and Hydra Aortic Valve are designed to address conditions like coronary artery disease and aortic stenosis. With a global presence, SMT is committed to advancing patient care through innovative medical solutions across multiple regions.
SMT's top competitors include InspireMD, Endospan and Vesper Medical.
SMT offers Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit.
SMT has made 2 acquisitions, including Vascular Concepts, and Zarek.
SMT has 79 investors. Key investors include SBI Mutual Fund, Kotak Mahindra Bank, Plutus, Madhuri Madhusudan Kela, and Samara Capital.
The valuation of SMT is $329.92M as of Jan 2023.